10x Genomics (TXG) reported a Q4 net loss late Wednesday of $0.40 per diluted share, compared with a loss of $0.41 a year earlier.

Analysts polled by FactSet expected a loss of $0.30.

Revenue for the quarter ended Dec. 31 was $165 million, down from $184 million a year earlier.

Analysts surveyed by FactSet expected $159.8 million.

The company said it expects full-year 2025 revenue to be between $610 million and $630 million.

Analysts polled by FactSet expect $631 million.

Shares of the company fell about 7% in after-hours activity.